ATLAB PHARMA is a product company dedicated to the development of radiolabeled antibodies for RadioImmunoTherapy applications. It aims to associate partners in order to validate and bring products to the patient and market.
Anti-cancer radio-antibodies ATLAB Pharma develops a beta-RIT drug for the treatment of prostate cancer. The drug uses Lutetium-177, a radio-isotope emitting beta radiations within a range of 250 microns, well adapted to destroy micro-metastasis. The product is in clinical Phase II studies. ATLAB Pharma also develops alpha-RIT products using astate-211. Astate-211 emits alpha radiations that deliver 100 times higher destructive energy than beta radiations within a range of 70 microns, well adapted to destroy isolated cancer cells. Products are currently in preclinical studies.